Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin
Diabetes Obesity and Metabolism2015Vol. 17(6), pp. 591–598
Citations Over TimeTop 10% of 2015 papers
Abstract
Ertugliflozin (1-25 mg/day) improved glycaemic control, body weight and blood pressure in patients with T2DM suboptimally controlled on metformin, and was well tolerated.
Related Papers
- → The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus(2011)90 cited
- → Tolerability of prolonged-release metformin (Glucophage® SR) in individuals intolerant to standard metformin — results from four UK centres(2007)34 cited
- → Glycemic Control by Combination Therapy of Sitagliptin-Metformin Versus Metformin Alone(2020)1 cited
- → Clinical diagnosis and Safety of Vildagliptin versus Sitagliptin with Metformin over Patients of Type-2 Diabetes Mellitus(2021)1 cited
- → Efficacy of Dapagliflozin & Metformin Vs Sitagliptin & Metformin in New patients with Type 2 Diabetic in HMC Hospital Peshawar(2022)